Yoshinobu Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoshinobu Saito has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Akihiko Gemma
Department of Pulmonary Medicine and Oncology, Nippon Medical School
15 shared publications- Arata Azuma
Mihara General Hospital, Saitama, Japan
14 shared publications - Akihiko Gemma
Nippon Medical School Tokyo Japan
11 shared publications Toru Tanaka
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo, 113-8603, Japan
9 shared publicationsMasahiro Seike
Department of Pulmonary Medicine and Oncology, Nippon Medical School
8 shared publicationsKoichiro Kamio
Department of Pulmonary Medicine and Oncology, Nippon Medical School
6 shared publications
Latest Publications
- Open Access
- 19 August 2025
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (1) , 160-173
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)
- 19 August 2025
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (1) , 160-173
Open AccessLong-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)
- 12 December 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (1) , 102-108
Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study
- 12 December 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (1) , 102-108
Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study
- Open Access
- 25 April 2024
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 91 (2) , 207-217
Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis
Background: Everolimus, a mammalian target of rapamycin inhibitor used as an antineoplastic drug, is associated with a remarkably high incidence of interstitial lung disease (ILD). The clinical and pathological characteristics of ILD caused by everolimus have not been thoroughly investigated; therefore, we aimed to elucidate the features of everolimus-associated ILD.Methods:We retrospectively reviewed the medical records of patients who received everolimus for cancer treatment at our hospital. Patient backgrounds were compared between the ILD and non-ILD groups. Chest computed tomography (CT), changes in biomarkers, and lung histopathological features were analyzed for ILD cases.Results:Sixty-six patients were reviewed, and ILD developed in 19. There were no differences in patient demographics between the ILD and non-ILD groups. The severity of ILD was grade 1 (G1) in 9 and grade 2 (G2) in 10 cases. Chest CT showed organizing pneumonia (OP) or a hypersensitive pneumonia pattern. The levels of lactate dehydrogenase, C-reactive protein, Krebs von den lungen-6, and surfactant protein-D (SP-D) at the onset of ILD were significantly higher than those at baseline. Analysis of G1 and G2 ILD subgroups showed a higher SP-D levels in the G2 subgroup. Five patients underwent lung biopsies; all specimens demonstrated alveolitis with lymphocytic infiltration and granulomatous lesions, and some had OP findings.Conclusions: Everolimus-associated ILD is mild and has a favorable prognosis. Patients with symptomatic ILD were more likely to have higher SP-D levels than those with asymptomatic ILD. Granulomatous lesions are an important pathological feature of everolimus-associated ILD.
- 25 April 2024
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 91 (2) , 207-217
Open AccessClinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis
Background: Everolimus, a mammalian target of rapamycin inhibitor used as an antineoplastic drug, is associated with a remarkably high incidence of interstitial lung disease (ILD). The clinical and pathological characteristics of ILD caused by everolimus have not been thoroughly investigated; therefore, we aimed to elucidate the features of everolimus-associated ILD.Methods:We retrospectively reviewed the medical records of patients who received everolimus for cancer treatment at our hospital. Patient backgrounds were compared between the ILD and non-ILD groups. Chest computed tomography (CT), changes in biomarkers, and lung histopathological features were analyzed for ILD cases.Results:Sixty-six patients were reviewed, and ILD developed in 19. There were no differences in patient demographics between the ILD and non-ILD groups. The severity of ILD was grade 1 (G1) in 9 and grade 2 (G2) in 10 cases. Chest CT showed organizing pneumonia (OP) or a hypersensitive pneumonia pattern. The levels of lactate dehydrogenase, C-reactive protein, Krebs von den lungen-6, and surfactant protein-D (SP-D) at the onset of ILD were significantly higher than those at baseline. Analysis of G1 and G2 ILD subgroups showed a higher SP-D levels in the G2 subgroup. Five patients underwent lung biopsies; all specimens demonstrated alveolitis with lymphocytic infiltration and granulomatous lesions, and some had OP findings.Conclusions: Everolimus-associated ILD is mild and has a favorable prognosis. Patients with symptomatic ILD were more likely to have higher SP-D levels than those with asymptomatic ILD. Granulomatous lesions are an important pathological feature of everolimus-associated ILD.
- Open Access
- 8 March 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (6) , 2100-2105
Interstitial lung disease with prolonged fever that occurred during long-term administration of olaparib in a 74-year-old ovarian cancer patient: Radiological features and considerations for preventing delayed diagnosis
- 8 March 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (6) , 2100-2105
Open AccessInterstitial lung disease with prolonged fever that occurred during long-term administration of olaparib in a 74-year-old ovarian cancer patient: Radiological features and considerations for preventing delayed diagnosis
- 23 August 2023
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 317, 104142
Increased CTGF expression in alveolar epithelial cells by cyclic mechanical stretch: Its mechanism and the therapeutic effect of pirfenidone
- 23 August 2023
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 317, 104142
Increased CTGF expression in alveolar epithelial cells by cyclic mechanical stretch: Its mechanism and the therapeutic effect of pirfenidone
- Open Access
- 25 August 2022
- Published by Medical Association of Nippon Medical School in Nihon Ika Daigaku Igakkai Zasshi
- Vol. 18 (3) , 289-293
Winter-onset Summer-type Hypersensitivity Pneumonitis Related to a Warm Climate: A Case Report and Review of the Literature
A 49-year-old man living on an island was admitted to our hospital in January with antibiotic-resistant intermittent fever, cough, and hypoxemia. Based on his medical history, imaging findings, and a positive test for anti-Trichosporon asahii antibody, we diagnosed summer-type hypersensitivity pneumonitis. A literature review of reported cases of summer-type hypersensitivity pneumonitis diagnosed in seasons other than summer showed that it is common in hot and humid environments as well as in warm regions. The possibility of summer-type hypersensitivity pneumonitis should be considered even in winter.
- 25 August 2022
- Published by Medical Association of Nippon Medical School in Nihon Ika Daigaku Igakkai Zasshi
- Vol. 18 (3) , 289-293
Open AccessWinter-onset Summer-type Hypersensitivity Pneumonitis Related to a Warm Climate: A Case Report and Review of the Literature
A 49-year-old man living on an island was admitted to our hospital in January with antibiotic-resistant intermittent fever, cough, and hypoxemia. Based on his medical history, imaging findings, and a positive test for anti-Trichosporon asahii antibody, we diagnosed summer-type hypersensitivity pneumonitis. A literature review of reported cases of summer-type hypersensitivity pneumonitis diagnosed in seasons other than summer showed that it is common in hot and humid environments as well as in warm regions. The possibility of summer-type hypersensitivity pneumonitis should be considered even in winter.
- Open Access
- 18 May 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2071080
Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination
Following COVID-19 vaccination, ipsilateral axillary and cervical lymphadenopathy may occur, called vaccine-related hypermetabolic lymphadenopathy, which is considered reactive lymphadenopathy. We report here a case of Kikuchi-Fujimoto disease, which occurred three months after vaccination with COVID-19 vaccine. The patient had cervical and axillary lymph node enlargement and a short-term fever that resolved spontaneously after the first and second vaccines. On the 90th day after the first vaccination, the patient developed a high fever and pathologically diagnosed necrotizing lymphadenitis in the axilla, which was diagnosed as Kikuchi-Fujimoto disease. Gallium scintigraphy showed localized swelling and strong uptake in the ipsilateral axilla. It implies the possibility of Kikuchi-Fujimoto Disease in axillary drainage lymph nodes in association with COVID-19 vaccine. Although only a few cases have been reported so far, this case is novel because of its later onset and diagnosis based on pathological and gallium scintigraphy imaging findings.
- 18 May 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2071080
Open AccessKikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination
Following COVID-19 vaccination, ipsilateral axillary and cervical lymphadenopathy may occur, called vaccine-related hypermetabolic lymphadenopathy, which is considered reactive lymphadenopathy. We report here a case of Kikuchi-Fujimoto disease, which occurred three months after vaccination with COVID-19 vaccine. The patient had cervical and axillary lymph node enlargement and a short-term fever that resolved spontaneously after the first and second vaccines. On the 90th day after the first vaccination, the patient developed a high fever and pathologically diagnosed necrotizing lymphadenitis in the axilla, which was diagnosed as Kikuchi-Fujimoto disease. Gallium scintigraphy showed localized swelling and strong uptake in the ipsilateral axilla. It implies the possibility of Kikuchi-Fujimoto Disease in axillary drainage lymph nodes in association with COVID-19 vaccine. Although only a few cases have been reported so far, this case is novel because of its later onset and diagnosis based on pathological and gallium scintigraphy imaging findings.
- 1 November 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 819-826
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan
- 1 November 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 819-826
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan
- 25 August 2021
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 88 (4) , 326-334
A Possible, Non-Invasive Method of Measuring Dynamic Lung Compliance in Patients with Interstitial Lung Disease Using Photoplethysmography
Background: Measuring lung compliance is useful for evaluating progression of interstitial lung disease (ILD), because reduced lung compliance due to fibrosis progression is the main cause of decreased vital capacity. However, because insertion of a balloon into the esophagus is invasive, lung compliance is rarely measured. A recently developed method uses fingertip photoplethysmography to estimate intra-thoracic pressure. This method non-invasively measures lung dynamic compliance (Cdyn) by simulta-neously measuring tidal volume. We evaluated the efficacy of this method in assessing ILD. Methods: This single-center, cross-sectional, observational study evaluated the efficacy of this method in patients with ILD and healthy controls. The primary outcome was estimated Cdyn (eCdyn), as deter-mined with this method. We also evaluated baseline characteristics that are potential confounding fac-tors for eCdyn. Results: Median eCdyn was significantly lower in the ILD group (n = 14) than in the control group (n = 49) (0.122 vs. 0.183; P = 0.011). In univariate regression analysis, eCdyn was significantly correlated with height, weight, forced vital capacity, forced expiratory volume in 1 second, diffusing capacity for carbon monoxide, and usual interstitial pneumonia. In multivariate regression analysis, weight (beta = 0.49, P = 0.011) and usual interstitial pneumonia (beta = 0.52, P = 0.007) were significantly correlated with eCdyn. Conclusions: Using photoplethysmography, we noted a significant reduction in Cdyn in patients with ILD. This novel non-invasive method is a promising tool for evaluating fibrosis progression in ILD.
- 25 August 2021
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 88 (4) , 326-334
A Possible, Non-Invasive Method of Measuring Dynamic Lung Compliance in Patients with Interstitial Lung Disease Using Photoplethysmography
Background: Measuring lung compliance is useful for evaluating progression of interstitial lung disease (ILD), because reduced lung compliance due to fibrosis progression is the main cause of decreased vital capacity. However, because insertion of a balloon into the esophagus is invasive, lung compliance is rarely measured. A recently developed method uses fingertip photoplethysmography to estimate intra-thoracic pressure. This method non-invasively measures lung dynamic compliance (Cdyn) by simulta-neously measuring tidal volume. We evaluated the efficacy of this method in assessing ILD. Methods: This single-center, cross-sectional, observational study evaluated the efficacy of this method in patients with ILD and healthy controls. The primary outcome was estimated Cdyn (eCdyn), as deter-mined with this method. We also evaluated baseline characteristics that are potential confounding fac-tors for eCdyn. Results: Median eCdyn was significantly lower in the ILD group (n = 14) than in the control group (n = 49) (0.122 vs. 0.183; P = 0.011). In univariate regression analysis, eCdyn was significantly correlated with height, weight, forced vital capacity, forced expiratory volume in 1 second, diffusing capacity for carbon monoxide, and usual interstitial pneumonia. In multivariate regression analysis, weight (beta = 0.49, P = 0.011) and usual interstitial pneumonia (beta = 0.52, P = 0.007) were significantly correlated with eCdyn. Conclusions: Using photoplethysmography, we noted a significant reduction in Cdyn in patients with ILD. This novel non-invasive method is a promising tool for evaluating fibrosis progression in ILD.
- Open Access
- 30 October 2020
- Published by Wiley in Cancer Science
- Vol. 112 (4) , 1506-1513
Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently, there are limited data available on the treatment of nivolumab‐induced ILD and its outcome. This retrospective cohort study based on a post–marketing study described the treatment of nivolumab‐induced ILD and its outcome in NSCLC patients in Japan through the assessment of clinical and chest imaging findings by an expert central review committee. Treatment details for patients who experienced a relapse of ILD were also analyzed. Of the 238 patients identified as having nivolumab‐induced ILD, 37 patients died of ILD. Corticosteroids were used in 207 (87.0%) patients. Of those, 172 (83.1%) patients responded well and survived and 35 (16.9%) died (most died during corticosteroid treatment). A total of nine patients experienced a relapse; at the time of relapse, four patients were taking nivolumab. Of those who were receiving corticosteroids at the time of relapse, three of four patients were taking low doses or had nearly completed dose tapering. All patients (except one, whose treatment was unknown) received corticosteroids for the treatment of relapse, but one patient died. Patients with NSCLC who experience nivolumab‐induced ILD are treated effectively with corticosteroids, and providing extra care when ceasing or reducing the corticosteroid dose may prevent relapse of ILD.
- 30 October 2020
- Published by Wiley in Cancer Science
- Vol. 112 (4) , 1506-1513
Open AccessTreatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently, there are limited data available on the treatment of nivolumab‐induced ILD and its outcome. This retrospective cohort study based on a post–marketing study described the treatment of nivolumab‐induced ILD and its outcome in NSCLC patients in Japan through the assessment of clinical and chest imaging findings by an expert central review committee. Treatment details for patients who experienced a relapse of ILD were also analyzed. Of the 238 patients identified as having nivolumab‐induced ILD, 37 patients died of ILD. Corticosteroids were used in 207 (87.0%) patients. Of those, 172 (83.1%) patients responded well and survived and 35 (16.9%) died (most died during corticosteroid treatment). A total of nine patients experienced a relapse; at the time of relapse, four patients were taking nivolumab. Of those who were receiving corticosteroids at the time of relapse, three of four patients were taking low doses or had nearly completed dose tapering. All patients (except one, whose treatment was unknown) received corticosteroids for the treatment of relapse, but one patient died. Patients with NSCLC who experience nivolumab‐induced ILD are treated effectively with corticosteroids, and providing extra care when ceasing or reducing the corticosteroid dose may prevent relapse of ILD.